Table of Contents Table of Contents
Previous Page  84 / 86 Next Page
Information
Show Menu
Previous Page 84 / 86 Next Page
Page Background

80

NCCN Guidelines for Patients

®

:

Pancreatic Cancer, Version 1.2017

Index

Index

adjuvant treatment

23–24, 37–41, 45–47, 49

bile ducts

6, 14, 16–18, 22, 29, 31, 34–35, 38, 43, 50,

56

bilirubin

14, 18, 35, 50, 56

biopsy

16, 18–19, 33–34, 37–38, 41–43, 48–51

blood tests

9, 18, 20, 34

borderline resectable

20, 24, 36, 42–48, 59

bypass

29, 37–38, 44–45, 50, 56

CA 19-9

18, 35

chemotherapy

22, 24–25, 27, 30–31, 39–43, 46–49,

52–59

clinical trial

8, 26–27, 39–43, 46–49, 52–59, 66

complementary and alternative medicine (CAM)

27

computed tomography (CT)

15–16, 19, 23, 30,

33–34, 39–40, 44, 46–47

distal pancreatectomy

22

ductal adenocarcinoma

4, 6

endoscopic retrograde cholangiopancreatography

(ERCP)

17, 19, 33–35, 50, 56

endoscopic ultrasound (EUS)

16, 19, 30, 33–34, 43,

51

imaging test

9, 14–17, 19, 33–34, 37, 43–44, 46

laparoscopy

18–19, 37, 43–44, 50, 56

locally advanced unresectable pancreatic cancer

32, 36, 45, 49–55

magnetic resonance cholangiopancreatography

(MRCP)

16, 33–34

magnetic resonance imaging (MRI)

16, 33, 44

metastatic pancreatic cancer

34, 38, 44–45, 53,

55–58

NCCN Member Institutions

79

NCCN Panel Members

78

pancreas

6–7, 11, 14–16, 18–20, 22, 29–30, 33–38,

41–42, 44, 48–49, 55–56, 59

pancreatoduodenectomy

22

pancreatic duct

6, 19

pancreatic protocol

15–16, 33–34, 44

performance status

20, 42, 49, 52–59

primary treatment

23, 37–39, 41–42, 44

radiation therapy

22–25, 30, 59

side effect

14, 18–19, 25–27, 42, 49, 52, 55–57

stage/staging

19–20, 24, 37, 43–44

supportive care

20, 29–31, 42, 49, 52–57, 59

surgery

18–20, 22–25, 27, 29–30, 35–42, 44–46,

48–50, 56, 59

targeted therapy

25, 27, 56

tissue test

18

total pancreatectomy

22

treatment plan

13–20, 27, 30

Whipple procedure

22